Tarsus Pharmaceuticals, Inc. (TARS)
72.30
-0.51
(-0.70%)
USD |
NASDAQ |
Aug 25, 10:43
Tarsus Pharmaceuticals Price to Book Value : 9.023 for Aug. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 9.086 |
| August 21, 2026 | 9.073 |
| August 20, 2026 | 8.922 |
| August 19, 2026 | 9.165 |
| August 18, 2026 | 8.864 |
| August 17, 2026 | 8.813 |
| August 14, 2026 | 8.636 |
| August 13, 2026 | 8.596 |
| August 12, 2026 | 8.738 |
| August 11, 2026 | 8.668 |
| August 10, 2026 | 8.456 |
| August 07, 2026 | 8.086 |
| August 06, 2026 | 8.153 |
| August 05, 2026 | 7.649 |
| August 04, 2026 | 7.626 |
| August 03, 2026 | 7.653 |
| July 31, 2026 | 7.368 |
| July 30, 2026 | 7.430 |
| July 29, 2026 | 7.303 |
| July 28, 2026 | 7.357 |
| July 27, 2026 | 7.503 |
| July 24, 2026 | 7.321 |
| July 23, 2026 | 7.311 |
| July 22, 2026 | 7.186 |
| July 21, 2026 | 7.146 |
| Date | Value |
|---|---|
| July 20, 2026 | 7.020 |
| July 17, 2026 | 7.469 |
| July 16, 2026 | 7.200 |
| July 15, 2026 | 7.176 |
| July 14, 2026 | 7.002 |
| July 13, 2026 | 7.402 |
| July 10, 2026 | 7.256 |
| July 09, 2026 | 8.004 |
| July 08, 2026 | 8.452 |
| July 07, 2026 | 8.804 |
| July 06, 2026 | 8.368 |
| July 02, 2026 | 8.167 |
| July 01, 2026 | 7.599 |
| June 30, 2026 | 7.855 |
| June 29, 2026 | 7.553 |
| June 26, 2026 | 7.757 |
| June 25, 2026 | 7.932 |
| June 24, 2026 | 8.274 |
| June 23, 2026 | 8.158 |
| June 22, 2026 | 7.836 |
| June 18, 2026 | 7.787 |
| June 17, 2026 | 7.712 |
| June 16, 2026 | 7.496 |
| June 15, 2026 | 7.625 |
| June 12, 2026 | 7.638 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Structure Therapeutics, Inc. | 2.614 |
| Alumis, Inc. | 6.756 |
| Veradermics, Inc. | 5.223 |
| ANI Pharmaceuticals, Inc. | 2.851 |
| Corcept Therapeutics, Inc. | 18.73 |
Price to Book Value Related Metrics
| PS Ratio | 5.120 |
| Price to Free Cash Flow | 55.43 |
| Price | 72.30 |
| Earnings Yield | -1.49% |
| Market Cap | 3.129B |